Gilead Sciences Inc. (NASDAQ:GILD) Sovaldi has broken sales records thanks to its ability to cure hepatitis C with a discrete, if costly, 12-week regimen. But rivals believe there’s plenty of room in the market for a speedier solution, and Bristol-Myers Squibb ($BMY) plans to use its ex-partner’s blockbuster to craft a four-week contender. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened today at $80.14 and is currently trading at $80.76. The stock showed a negative weekly performance of -0.99%.
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) said the Food and Drug Administration accepted for priority review the company’s new drug application for its investigational antibiotic for complicated urinary tract and complicated intra-abdominal infections. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) stock opened at $70.95, in current trading session and currently is at $71.50, by gaining 4.30%. The 52 week range of $48.23 – $82.12. Company’s market capitalization is 5.38 billion.
Equities researchers at ISI Group started coverage on shares of Mast Therapeutics Inc. (NASDAQ:MSTX) in a research report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “reduce” rating on the stock. Mast Therapeutics Inc. (NYSEMKT:MSTX) stock is currently trading at $0.676. The EPS of the stock is -0.26. Company’s market capitalization is 77.13 million.
IsoRay, Inc. (NYSEMKT:ISR) announced that it has entered into two (2) international distribution agreements: the first with MedikorPharma-Ural LLC for the Russian market and the other with Surgicorp SRL for the Peruvian market. IsoRay is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gynecologic (“gyn”) cancer. IsoRay, Inc. (NYSEMKT:ISR) stock opened the session at $2.67, and now is at $2.60. The 52 week range of the IsoRay, Inc. (NYSEMKT:ISR) stock remained $0.44 – $3.77 and the day range was $2.60 – $2.75.
StemCells (NASDAQ:STEM) announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. Interim results for the current AMD trial show a 70 percent reduction in the rate of geographic atrophy (GA) as compared to the control eye and a 65 percent reduction in the rate of GA as compared to the expected natural history of the disease following a single dose of the Company’s proprietary HuCNS-SC® human neural stem cells. StemCells Inc. (NASDAQ:STEM) stock opened today at $2.16 and is currently trading at $2.26. The stock showed a positive weekly performance of 35.71%.